OrganiGram Ebit vs Cost Of Revenue Analysis
OGI Stock | USD 1.52 0.01 0.66% |
OrganiGram Holdings financial indicator trend analysis is much more than just breaking down OrganiGram Holdings prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether OrganiGram Holdings is a good investment. Please check the relationship between OrganiGram Holdings Ebit and its Cost Of Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OrganiGram Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more detail on how to invest in OrganiGram Stock please use our How to Invest in OrganiGram Holdings guide.
Ebit vs Cost Of Revenue
Ebit vs Cost Of Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of OrganiGram Holdings Ebit account and Cost Of Revenue. At this time, the significance of the direction appears to have pay attention.
The correlation between OrganiGram Holdings' Ebit and Cost Of Revenue is -0.78. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of OrganiGram Holdings, assuming nothing else is changed. The correlation between historical values of OrganiGram Holdings' Ebit and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of OrganiGram Holdings are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Ebit i.e., OrganiGram Holdings' Ebit and Cost Of Revenue go up and down completely randomly.
Correlation Coefficient | -0.78 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Ebit
Cost Of Revenue
Cost of Revenue is found on OrganiGram Holdings income statement and represents the costs associated with goods and services OrganiGram Holdings provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most indicators from OrganiGram Holdings' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into OrganiGram Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OrganiGram Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more detail on how to invest in OrganiGram Stock please use our How to Invest in OrganiGram Holdings guide.As of now, OrganiGram Holdings' Selling General Administrative is increasing as compared to previous years. The OrganiGram Holdings' current Enterprise Value Over EBITDA is estimated to increase to 31.81, while Discontinued Operations is projected to decrease to (35.9 K).
2023 | 2024 (projected) | Reconciled Depreciation | 28.6M | 16.1M | Interest Income | 11.8M | 12.4M |
OrganiGram Holdings fundamental ratios Correlations
Click cells to compare fundamentals
OrganiGram Holdings Account Relationship Matchups
High Positive Relationship
High Negative Relationship
OrganiGram Holdings fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 417.6M | 554.0M | 577.1M | 298.5M | 343.2M | 251.2M | |
Other Current Liab | (11.6M) | 6.3M | 12.0M | 2.3M | 2.6M | 2.1M | |
Total Current Liabilities | 29.1M | 26.3M | 55.3M | 22.4M | 25.8M | 18.3M | |
Total Stockholder Equity | 299.5M | 479.8M | 508.1M | 271.6M | 312.4M | 202.3M | |
Net Debt | 79.1M | (50.4M) | (65.2M) | (30.2M) | (27.1M) | (25.8M) | |
Retained Earnings | (144.9M) | (275.6M) | (289.9M) | (538.5M) | (484.7M) | (460.4M) | |
Cash | 24.6M | 55.4M | 68.5M | 33.9M | 38.9M | 27.4M | |
Non Current Assets Total | 247.4M | 293.4M | 355.5M | 142.5M | 163.9M | 144.2M | |
Non Currrent Assets Other | 8.0M | 31.1M | 32.4M | 19.1M | 22.0M | 12.7M | |
Cash And Short Term Investments | 74.7M | 183.8M | 98.9M | 33.9M | 38.9M | 58.5M | |
Net Receivables | 17.0M | 21.0M | 43.9M | 27.5M | 31.6M | 33.2M | |
Common Stock Shares Outstanding | 43.2M | 64.0M | 77.2M | 81.3M | 93.5M | 98.2M | |
Liabilities And Stockholders Equity | 417.6M | 554.0M | 577.1M | 298.5M | 343.2M | 251.2M | |
Other Stockholder Equity | 23.7M | 24.7M | 28.3M | 33.2M | 38.2M | 40.1M | |
Total Liab | 118.1M | 74.2M | 69.0M | 26.8M | 30.9M | 48.9M | |
Total Current Assets | 170.2M | 260.6M | 221.6M | 156.0M | 179.4M | 119.0M | |
Property Plant And Equipment Net | 247.4M | 235.9M | 259.8M | 99.0M | 113.9M | 135.1M | |
Accounts Payable | 17.5M | 19.0M | 40.9M | 20.0M | 23.0M | 15.8M | |
Non Current Liabilities Total | 89.0M | 47.9M | 13.8M | 4.4M | 5.1M | 4.8M | |
Accumulated Other Comprehensive Income | 23.8M | 24.6M | 28.3M | 33.2M | 38.2M | 40.1M | |
Common Stock | 420.7M | 730.8M | 769.7M | 776.9M | 893.4M | 938.1M | |
Short Long Term Debt Total | 103.7M | 5.0M | 3.4M | 3.7M | 3.3M | 3.2M | |
Other Liab | 231K | 43.1M | 11.4M | 771K | 886.7K | 842.3K | |
Net Tangible Assets | 297.8M | 462.8M | 451.8M | 261.0M | 300.1M | 258.4M | |
Other Assets | 8.7M | 35.4M | 33.1M | 1.0 | 1.15 | 1.09 | |
Long Term Debt | 46.1M | 103.7M | 230K | 155K | 178.3K | 169.3K | |
Short Term Investments | 380K | 50.1M | 128.5M | 30.4M | 35.0M | 46.6M | |
Inventory | 71.8M | 48.8M | 68.3M | 81.0M | 93.1M | 56.5M | |
Other Current Assets | 6.7M | 7.0M | 10.6M | 13.7M | 15.8M | 10.0M | |
Deferred Long Term Liab | 698K | 7K | 30K | 391K | 449.7K | 354.3K | |
Long Term Investments | 11.1M | 7.0M | 6.1M | 7.1M | 8.1M | 4.3M | |
Short Long Term Debt | 421K | 3.5M | 11.6M | 80K | 92K | 87.4K | |
Short Term Debt | 11.6M | 1.1M | 996K | 76K | 87.4K | 83.0K | |
Intangible Assets | 1.8M | 2.7M | 14.3M | 10.6M | 12.2M | 12.8M |
Currently Active Assets on Macroaxis
When determining whether OrganiGram Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OrganiGram Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organigram Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organigram Holdings Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OrganiGram Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more detail on how to invest in OrganiGram Stock please use our How to Invest in OrganiGram Holdings guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OrganiGram Holdings. If investors know OrganiGram will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OrganiGram Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.80) | Revenue Per Share 1.835 | Quarterly Revenue Growth (0.14) | Return On Assets (0.06) | Return On Equity (0.55) |
The market value of OrganiGram Holdings is measured differently than its book value, which is the value of OrganiGram that is recorded on the company's balance sheet. Investors also form their own opinion of OrganiGram Holdings' value that differs from its market value or its book value, called intrinsic value, which is OrganiGram Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OrganiGram Holdings' market value can be influenced by many factors that don't directly affect OrganiGram Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OrganiGram Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if OrganiGram Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OrganiGram Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.